EGFR and non-small cell lung carcinoma: The NeoADAURA trial is an ongoing, phase III trial that will look at MPR and survival outcomes in patients with stage II-IIIB, N2, EGFR-mutated NSCLC who received neoadjuvant osimertinib with or without chemotherapy (51).